Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

JACC: Cardiovascular Interventions

Volumn 11, Issue 2, 2018, Pages 181-191

  Cavallari, Larisa H ^a   Lee, Craig R ^b   Beitelshees, Amber L ^c   Cooper DeHoff, Rhonda M ^a,d   Duarte, Julio D ^a,e   Voora, Deepak ^f   Kimmel, Stephen E ^g   McDonough, Caitrin W ^a   Gong, Yan ^a   Dave, Chintan V ^a   Pratt, Victoria M ^h   Alestock, Tameka D ^c   Anderson, R David ^d   Alsip, Jorge ⁱ   Ardati, Amer K ^j   Brott, Brigitta C ⁱ   Brown, Lawrence ^k   Chumnumwat, Supatat ^e   Clare Salzler, Michael J ^d   Coons, James C ^l   Denny, Joshua C ^m   Dillon, Chrisly ⁿ   Elsey, Amanda R ^a   Hamadeh, Issam S ^a,u   Harada, Shuko ^o   Hillegass, William B ^p   Hines, Lindsay ^q   Horenstein, Richard B ^c   Howell, Lucius A ^r   Jeng, Linda J B ^c   Kelemen, Mark D ^c   Lee, Yee Ming ^e,v   Magvanjav, Oyunbileg ^a   Montasser, May ^c   Nelson, David R ^d   Nutescu, Edith A ^e   Nwaba, Devon C ^c   Pakyz, Ruth E ^c   Palmer, Kathleen ^c   Peterson, Josh F ^m   Pollin, Toni I ^c   Quinn, Alison H ^e   Robinson, Shawn W ^c,k   Schub, Jamie ^c   Skaar, Todd C ^s   Smith, D Max ^a   Sriramoju, Vindhya B ^r   Starostik, Petr ^d   Stys, Tomasz P ^t   Stevenson, James M ^l   Varunok, Nicholas ^r   Vesely, Mark R ^c,k   Wake, Dyson T ^a,w   Weck, Karen E ^r   Weitzel, Kristin W ^a   Wilke, Russell A ^t   Willig, James ⁱ   Zhao, Richard Y ^c   Kreutz, Rolf P ^s   Stouffer, George A ^r   Empey, Philip E ^l   Limdi, Nita A ⁿ   Shuldiner, Alan R ^c   Winterstein, Almut G ^a,d   Johnson, Julie A ^a,d   more..

^a UNIVERSITY OF FLORIDA   (United States)

^b University of North Carolina   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ University of Alabama at Birmingham   (United States)

^j UNIVERSITY OF ILLINOIS   (United States)

^k BALTIMORE VA MEDICAL CENTER   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

^m VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁿ The University of Alabama at Birmingham   (United States)

^o University of Alabama at Birmingham   (United States)

^p UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^q UNIVERSITY OF NORTH DAKOTA   (United States)

^r UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^s INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t UNIVERSITY OF SOUTH DAKOTA   (United States)

^u LEVINE CANCER INSTITUTE   (United States)

^v UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^w NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

more..

Author keywords

antiplatelet therapy; cardiovascular events; clopidogrel; CYP2C19; percutaneous coronary intervention; pharmacogenomics

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; ADULT; ALLELE; ALTERNATIVE MEDICINE; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CLINICAL OUTCOME; CORONARY ARTERY DISEASE; DEATH; FEMALE; FOLLOW UP; GENOTYPE; HEART INFARCTION; HUMAN; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHENOTYPE; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; UNSTABLE ANGINA PECTORIS; AGED; CLINICAL DECISION MAKING; CLINICAL TRIAL; DRUG RESISTANCE; GENETICS; MORTALITY; PATIENT SELECTION; PHARMACOGENETIC TESTING; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; CLINICAL DECISION-MAKING; CLOPIDOGREL; CYTOCHROME P-450 CYP2C19; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PHARMACOGENOMIC TESTING; PHARMACOGENOMIC VARIANTS; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TICAGRELOR; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 85032917144     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2017.07.022     Document Type: Article

References (33)

1. Levine, G.N., Bates, E.R., Bittl, J.A., et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 68, 2016 1082–11.
2. Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58 (2011), e44–e122.
3. Mega, J.L., Close, S.L., Wiviott, S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009), 354–362.
4. Shuldiner, A.R., O'Connell, J.R., Bliden, K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302 (2009), 849–857.
5. Mega, J.L., Simon, T., Collet, J.P., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304 (2010), 1821–1830.
6. Sorich, M.J., Rowland, A., McKinnon, R.A., Wiese, M.D., CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet 7 (2014), 895–902.
7. Wallentin, L., James, S., Storey, R.F., et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376 (2010), 1320–1328.
8. Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
9. Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
10. Mega, J.L., Close, S.L., Wiviott, S.D., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119 (2009), 2553–2560.
11. Lee, J.A., Lee, C.R., Reed, B.N., et al. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics 16 (2015), 303–313.
12. Shuldiner, A.R., Palmer, K., Pakyz, R.E., et al. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-Platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet 166C (2014), 76–84.
13. Weitzel, K.W., Elsey, A.R., Langaee, T.Y., et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet 166C (2014), 56–67.
14. Peterson, J.F., Field, J.R., Unertl, K.M., et al. Physician response to implementation of genotype-tailored antiplatelet therapy. Clin Pharmacol Ther 100 (2016), 67–74.
15. Ford, I., Norrie, J., Pragmatic trials. N Engl J Med 375 (2016), 454–463.
16. Loudon, K., Treweek, S., Sullivan, F., Donnan, P., Thorpe, K.E., Zwarenstein, M., The PRECIS-2 tool: designing trials that are fit for purpose. BMJ, 350, 2015, h2147.
17. Sox, H.C., Lewis, R.J., Pragmatic trials: practical answers to “real world” questions. JAMA 316 (2016), 1205–1206.
18. Cavallari, L.H., Beitelshees, A.L., Blake, K.V., et al. The IGNITE Pharmacogenetics Working Group: an opportunity for building evidence with pharmacogenetic implementation in a real-world setting. Clin Transl Sci 10 (2017), 143–146.
19. Caudle, K.E., Dunnenberger, H.M., Freimuth, R.R., et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med 19 (2017), 215–223.
20. Scott, S.A., Sangkuhl, K., Stein, C.M., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94 (2013), 317–323.
21. Austin, P.C., A tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality. Multivariate Behav Res 46 (2011), 119–151.
22. Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
23. Deiman, B.A., Tonino, P.A., Kouhestani, K., et al. Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands. Neth Heart J 24 (2016), 589–599.
24. Sanchez-Ramos, J., Davila-Fajardo, C.L., Toledo Frias, P., et al. Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent. Int J Cardiol 225 (2016), 289–295.
25. Xie, X., Ma, Y.T., Yang, Y.N., et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. Int J Cardiol 168 (2013), 3736–3740.
26. Shen, D.L., Wang, B., Bai, J., et al. Clinical value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a Chinese population. J Cardiovasc Pharmacol 67 (2016), 232–236.
27. Holmes, D.R. Jr., Dehmer, G.J., Kaul, S., Leifer, D., O'Gara, P.T., Stein, C.M., ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. J Am Coll Cardiol 56 (2010), 321–341.
28. Sorich, M.J., Vitry, A., Ward, M.B., Horowitz, J.D., McKinnon, R.A., Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 8 (2010), 1678–1684.
29. Pare, G., Mehta, S.R., Yusuf, S., et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363 (2010), 1704–1714.
30. Doll, J.A., Neely, M.L., Roe, M.T., et al. Impact of CYP2C19 metabolizer status on patients with ACS treated with prasugrel versus clopidogrel. J Am Coll Cardiol 67 (2016), 936–947.
31. Sherwood, M.W., Wiviott, S.D., Peng, S.A., et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J Am Heart Assoc, 3, 2014, e000849.
32. 12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol 117 (2016), 1439–1443.
33. Serebruany, V.L., Atar, D., Assessment of bleeding events in clinical trials—proposal of a new classification. Am J Cardiol 99 (2007), 288–290.